Loading...
Loading...
Celgene International Sàrl, a subsidiary of Celgene Corporation
CELG today announced it will request a re-examination of the negative opinion announced by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorisation Application (MAA) submitted for ISTODAX® (romidepsin) for the treatment of relapsed or refractory peripheral t-cell lymphoma (PTCL).
During the regulatory review process, it was acknowledged that romidepsin demonstrated anti-tumor activity, however, in the absence of a reference treatment in the clinical trial submitted to support the application, the committee was unable to agree that the benefit/risk relationship of romidepsin was demonstrated.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in